Dec 19 (Reuters) - Merck's (MRK.N), opens new tab experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form ...

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy. The two studies – IMPOWER 22 ...

Merck (NYSE:MRK) on Thursday indicated a mixed outcome in two pivotal Phase 3 trials for its experimental HIV therapy islatravir, administered orally in combination with its FDA-approved HIV ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.

“We are committed to advancing our clinical programs for islatravir in combination with other antiretrovirals as potential options to help address the needs of people living with HIV.

In one of the studies, Merck's combination was shown to be safe and "non-inferior" to Gilead Sciences' top-selling HIV drug Biktarvy. However, the treatment was not superior to Biktarvy in ...